Delmer Dee Raibourn III
@Avidity Partners Management Lp
Latest period2024 - Q3ReportedManaged Assets$1.96BTotal holdings81
Assets growth rate-16.7%Assets growth rate (2-Q avg)-20.41%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Avidity Partners Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 81 positions.
Assets under management
The assets under management (AUM) of Avidity Partners Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.96B in assets, with a quarterly growth rate of -16.7% and a 2-quarter average growth rate of -20.41%. The portfolio is managed by Delmer Dee Raibourn III, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
UNHUnitedhealth Group Inc
| 2.61% | $51.101M 87,400 shares@ $584.68 avg price | New Position |
HUMHumana Inc
| 2.1% | $41.081M 129,700 shares@ $316.74 avg price | New Position |
CNTACentessa Pharmaceuticals Plc
| 1.74% | $34.091M 2.132M shares@ $15.99 avg price | New Position |
KYMRKymera Therapeutics Inc
| 1.21% | $23.665M 500,000 shares@ $47.33 avg price | New Position |
BMRNBiomarin Pharmaceutical Inc
| 1.15% | $22.493M 320,000 shares@ $70.29 avg price | New Position |
ORKAOruka Therapeutics Inc
| 0.99% | $19.386M 790,926 shares@ $24.51 avg price | New Position |
TERNTerns Pharmaceuticals Inc
| 0.91% | $17.796M 2.134M shares@ $8.34 avg price | New Position |
ASNDAscendis Pharma A S
| 0.91% | $17.768M 119,000 shares@ $149.31 avg price | New Position |
BNTXBiontech Se
| 0.88% | $17.222M 145,000 shares@ $118.77 avg price | New Position |
ORICOric Pharmaceuticals Inc
| 0.76% | $14.833M 1.447M shares@ $10.26 avg price | New Position |